Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor in Relapsed/Refractory PTCL and CTCL
NCT02314247Phase 2Terminated
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Feb 2015
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of selinexor in peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL), sponsored by Karyopharm Therapeutics Inc.. Started Feb 2015; status: terminated.
02
Drugs
selinexor
03
Conditions
peripheral T-cell lymphoma (PTCL)cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT02314247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02314247.